Angiotensin-converting enzyme inhibition decreases growth factor expression in the neonatal rat kidney

被引:35
|
作者
Yoo, KH
Wolstenholme, JT
Chevalier, RL
机构
[1] UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,SCH MED,CHARLOTTESVILLE,VA 22908
[2] KOREA UNIV,DEPT PEDIAT,SEOUL 136701,SOUTH KOREA
关键词
D O I
10.1203/00006450-199711000-00006
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The renin-angiotensin system plays an important role in renal growth and development: exposure of the fetus or neonate to angiotensin-converting enzyme (ACE) inhibitors increases mortality and results in growth retardation and abnormal renal development. This study was designed to investigate the effects of ACE inhibition in the neonatal rat on the expression of genes known to modulate renal cellular proliferation, cell interactions, and extracellular matrix, Newborn rat pups were treated with enalapril (30 mg/kg/d) or vehicle for 14 d, and kidneys were removed for Northern analysis of mRNA for transforming growth factor-beta 1 (TGF-beta 1), prepro epidermal growth factor (EGF), clusterin, and renin, Distribution of TGF-beta 1, EGF, and clusterin was also determined by immunohistochemistry. Enalapril treatment resulted in 40% mortality by d 14, reduced body and kidney weight, decreased glomerular area, and caused tubular dilatation (p < 0.05 versus vehicle group). Enalapril decreased renal TGF-beta 1 and EGF mRNA expression, and increased renal clusterin and renin expression (p < 0.05), Renal tubular immunoreactive EGF was decreased, and clusterin was increased by enalapril treatment. These results indicate that ACE inhibition in the developing kidney reduces the renal expression of critical growth factors, which may account for renal growth impairment, Clusterin expression may increase either due to blockade of tonic angiotensin-mediated inhibition, or as an adaptive response to renal ischemia.
引用
收藏
页码:588 / 592
页数:5
相关论文
共 50 条
  • [41] INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME - THERAPEUTIC IMPLICATIONS
    ROTMENSCH, HH
    VLASSES, PH
    FERGUSON, RK
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1982, 18 (10): : 981 - 985
  • [42] Angiotensin-converting enzyme inhibition and fibrinolytic balance
    Matsumoto, Tetsuya
    Horie, Minoru
    HYPERTENSION RESEARCH, 2011, 34 (04) : 448 - 449
  • [43] The angiotensin-converting enzyme inhibition post revascularization
    Kjoller-Hansen, L
    Steffensen, R
    Grande, P
    EUROPEAN HEART JOURNAL, 2000, 21 : 168 - 168
  • [44] ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND THE HEART
    GAVRAS, H
    HYPERTENSION, 1994, 23 (06) : 813 - 818
  • [45] Angiotensin-converting enzyme inhibition: Facts and fiction
    Tamimi, N
    El Nahas, AM
    NEPHRON, 2000, 84 (04): : 299 - 304
  • [46] Cardiovascular protection by angiotensin-converting enzyme inhibition
    Ferrari, Roberto
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2009, 11 (0E) : E1 - E3
  • [47] Bradykinin and inhibition of angiotensin-converting enzyme in hypertension
    Azizi, M
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (12): : 967 - 967
  • [48] INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME BY DIPEPTIDE ANALOGS
    SCHWAB, A
    MACERATA, R
    ROGERS, W
    BARTON, J
    SKILES, J
    KHANDWALA, A
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1984, 45 (03): : 339 - 345
  • [49] A DECADE OF ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITION
    LARAGH, JH
    AMERICAN JOURNAL OF MEDICINE, 1992, 92 : S3 - S7
  • [50] ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND PROSTAGLANDINS
    SWARTZ, SL
    WILLIAMS, GH
    AMERICAN JOURNAL OF CARDIOLOGY, 1982, 49 (06): : 1405 - 1409